LEADER 01580nam  2200421   450 
001 9910708301403321
005 20221024174530.0
035   $a(CKB)3450000000002483
035   $a(NjHacI)993450000000002483
035   $a(OCoLC)54898752$z(OCoLC)55048108
035   $a(EXLCZ)993450000000002483
100   $a20221024d2002      uy             0
101 0 $aeng
135   $aur|||||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aS-adenosyl-L-methionine for treatment of depression, osteoarthritis, and liver disease /$fMary Hardy [and eleven others] editors
210  1$aRockville (MD) :$cAgency for Healthcare Research and Quality (US),$d[2002]
210  4$dİ2002
215   $a1 online resource (3 pages) $cillustrations
225 1 $aEvidence report/technology assessment,$x1530-4396 ;$vno. 64
225 1 $aAHRQ publication ;$vno. 02-E 034
300   $aTitle from title screen (viewed Apr. 7, 2004).
300   $a"October 2002."
320   $aIncludes bibliographical references.
606   $aDepression, Mental$xChemotherapy
615  0$aDepression, Mental$xChemotherapy.
676   $a616.8527061
702   $aHardy$b Mary
712 02$aUnited States.$bAgency for Healthcare Research and Quality.
712 02$aSouthern California Evidence-Based Practice Center/RAND.
801  0$bNjHacI
801  1$bNjHacl
906   $aBOOK
912   $a9910708301403321
996   $aS-adenosyl-L-methionine for treatment of depression, osteoarthritis, and liver disease$93295198
997   $aUNINA